Cost-Effectiveness of Dexamphetamine and Methylphenidate for the Treatment of Childhood Attention Deficit Hyperactivity Disorder

Donnelly, Marie; Haby, Michelle M.; Carter, Rob; Andrews, Gavin; Vos, Theo

doi:10.1080/j.1440-1614.2004.01422.x

Cited by 37 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ADHD could be diagnosed according to either the International Classification of Diseases, 10th revision (ICD-10), or the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) [11]. In Australia, short-acting dexamphetamine and long-acting methylphenidate are prescribed for ADHD treatment with stimulants, and considered cost-effective interventions for ADHD, since these are subsidized by the Government under the Pharmaceutical Benefits Scheme [11, 13]. …”

Section: Methodsmentioning

confidence: 99%

Identifying cross-cultural variations in psychostimulant use for attention deficit hyperactivity disorder using linked data

Ghosh

Holman

Preen

2017

Child Adolesc Psychiatry Ment Health

View full text Add to dashboard Cite

BackgroundTo validate the association between country-of-birth and disparities in the stimulant use for ADHD among individuals in Western Australia.MethodsUsing linked data, a population-based retrospective cohort of individuals admitted to hospital before age 25 years was followed through to identify having stimulants for ADHD in 2003–2007. Multivariate logistic and linear regressions were used to characterise associations between stimulants and country-of-birth, geographical remoteness and socioeconomic status.ResultsOf 679,645 individuals, 14,122 (2.1%) had a record of having stimulants for ADHD. Of these, 205 (1.5%) were born in Africa, Asia, Middle-East or South America, while 13,664 (96.8%) were born in Australia/New Zealand, Europe or North America. Individuals with traditionally non-Anglophonic backgrounds were around one-half as likely to have stimulants as individuals with Anglophonic backgrounds (OR = 0.53, 95% CI 0.46–0.61, p < 0.001). Non-Anglophones were an average of 2.7 years older than Anglophones at onset of having stimulants. Individuals from remote and disadvantaged backgrounds had stimulants at younger ages than individuals living in metropolitan areas and with least disadvantage.ConclusionsThe results highlight the importance of identifying factors underlying cultural differences in stimulant treatment for ADHD. Improving awareness of cultural variations may foster trust and rapport between patients and clinicians, and so better facilitate the appropriate and effective treatment of ADHD for each patient.

show abstract

Section: Methodsmentioning

confidence: 99%

Identifying cross-cultural variations in psychostimulant use for attention deficit hyperactivity disorder using linked data

Ghosh

Holman

Preen

2017

Child Adolesc Psychiatry Ment Health

View full text Add to dashboard Cite

show abstract

“…With an estimated prevalence of B5 to 8% in children, ADHD is among the most common childhood neurobehavioral disorders, and frequently persists into adolescence and adulthood Faraone and Biederman, 2005;Faraone et al, 2006;Mick et al, 2004). Given the established increased morbidity associated with ADHD, including impaired academic, occupational, and social functioning, increased rates of substance abuse, traffic accidents, persistent neuropsychological impairments, and the attendant increased costs to society Donnelly et al, 2004;Guevara et al, 2001;Secnik et al, 2005;Vos et al, 2005), determining the underlying neural substrate of ADHD is of great import.…”

Section: Introductionmentioning

confidence: 99%

Attention-Deficit/Hyperactivity Disorder and Attention Networks

Bush

2009

Neuropsychopharmacol

294

251

View full text Add to dashboard Cite

Research attempting to elucidate the neuropathophysiology of attention-deficit/hyperactivity disorder (ADHD) has not only shed light on the disorder itself, it has simultaneously provided new insights into the mechanisms of normal cognition and attention. This review will highlight and integrate this bidirectional flow of information. Following a brief overview of ADHD clinical phenomenology, ADHD studies will be placed into a wider historical perspective by providing illustrative examples of how major models of attention have influenced the development of neurocircuitry models of ADHD. The review will then identify major components of neural systems potentially relevant to ADHD, including attention networks, reward/feedbackbased processing systems, as well as a 'default mode' resting state network. Further, it will suggest ways in which these systems may interact and be influenced by neuromodulatory factors. Recent ADHD imaging data will be selectively provided to both illustrate the field's current level of knowledge and to show how such data can inform our understanding of normal brain functions. The review will conclude by suggesting possible avenues for future research.

show abstract

“…Furthermore, the model adopted in this study was more complete than those used in previous investigations. 16,18 Second, the high ICER values for treatment success could be even higher than those presented in this analysis. Due to the high dropout rates, most patients may leave treatment, for a variety of reasons, including lack of efficacy.…”

Section: Discussionmentioning

confidence: 53%

“…In contrast, countries like the UK, 16 the U.S., 17 Australia, 18 and Spain 19 are largely focusing on economic analysis and health policy for ADHD treatment. To date, a systematic review found 14 studies from different countries on the theme.…”

Section: Introductionmentioning

confidence: 99%

Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil

Maia

Stella²,

Wagner

et al. 2015

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

Objective: To perform a cost-utility analysis on the treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate immediate-release (MPH-IR) in children and adolescents from Brazil. Method: A Markov model was constructed to compare MPH-IR vs. no treatment. A 24-week naturalistic study was conducted to collect transition probabilities and utility data. Effectiveness was expressed as quality-adjusted life-years (QALY), and costs reported in 2014 international dollars (I$). The perspective was the Brazilian Unified Health System as payer, and the time horizon was 6 years. Results: Of 171 patients, 73 provided information at baseline, and 56 at week 24. Considering the MPH-IR monthly cost of I$ 38, the incremental cost-effectiveness ratio (ICER) of treatment was I$ 9,103/QALY for children and I$ 11,883/QALY for adolescents. In two-way sensitivity analysis, considering one Gross National Product per capita (I$ 11,530) as willingness-to-pay, a cost of no-treatment lower than I$ 45/month would render MPH-IR a cost-saving strategy. Discussion: MPH-IR treatment of children and adolescents is cost-effective for ADHD patients from the Brazilian public health system perspective. Both patients and the healthcare system might benefit from such a strategy. Trial registration number: NCT01705613.

show abstract

Cost-Effectiveness of Dexamphetamine and Methylphenidate for the Treatment of Childhood Attention Deficit Hyperactivity Disorder

Cited by 37 publications

References 43 publications

Identifying cross-cultural variations in psychostimulant use for attention deficit hyperactivity disorder using linked data

Identifying cross-cultural variations in psychostimulant use for attention deficit hyperactivity disorder using linked data

Attention-Deficit/Hyperactivity Disorder and Attention Networks

Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil

Contact Info

Product

Resources

About